As of Feb 20, 2025, Johnson & Johnson's Discounted Cash Flow (DCF) valuation estimates its share price at $227.5. This suggests it may be undervalued by 42.5% compared to its current price of around $159.6, using a WACC of 7.1% and growth rates of 3.0%.
As of Feb 20, 2025, Johnson & Johnson's Weighted Average Cost of Capital (WACC) is approximately 7.1%.
As of Feb 20, 2025, Johnson & Johnson's Enterprise Value (EV) is approximately $553.8B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.